ACTR-13. EPIDERMAL GROWTH FACTOR RECEPTOR (EGFR) AMPLIFICATION RATES OBSERVED IN SCREENING PATIENTS FOR RANDOMIZED CLINICAL TRIALS IN GLIOBLASTOMA

BACKGROUND: EGFR is a key oncogenic target for the treatment of glioblastoma. EGFR amplification is detected in ~50% of tumors. Depatuxizumab mafodotin (depatux-m), formerly called ABT-414, is a tumor-specific antibody-drug conjugate that preferentially targets tumors with EGFR amplification. Herein...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Neuro Oncol
Autors principals: van den Bent, Martin, Roberts-Rapp, Lisa A, Ansell, Peter J, Lee, James, Looman, Jim, Bain, Earle, Ocampo, Christopher, Holen, Kyle D, Gomez, Erica J, Lassman, Andrew B
Format: Artigo
Idioma:Inglês
Publicat: Oxford University Press 2017
Matèries:
Abstracts
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC5693085/
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/neuonc/nox168.010
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars